|
1.
|
|
14 p, 1.6 MB |
Characteristics of subjective cognitive decline associated with amyloid positivity
/
Janssen, Olin (Maastricht University. School for Mental Health and Neuroscience) ;
Jansen, W.J. (Maastricht University. School for Mental Health and Neuroscience) ;
Vos, S.J.B. (Maastricht University. School for Mental Health and Neuroscience) ;
Boada, Mercè (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Parnetti, Lucilla (Section of Neurology. Center for Memory Disturbances - Lab. of Clinical Neurochemistry. Department of Medicine and Surgery. University of Perugia) ;
Gabryelewicz, T. (Department of Neurodegenerative Disorders. Mossakowski Medical Research Centre. Polish Academy of Sciences) ;
Fladby, T. (Department of Neurology. Akershus University Hospital) ;
Molinuevo, José Luis (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Villeneuve, S. (Centre for Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre) ;
Hort, J. (International Clinical Research Center. St. Anne's University Hospital) ;
Epelbaum, S. (Inserm Sorbonne Université. Inria. Aramis project-team. Paris Brain Institute - Institut du Cerveau (ICM)) ;
Lleó, Alberto (Institut d'Investigació Biomèdica Sant Pau) ;
Engelborghs, Sebastiaan (Vrije Universiteit Brussel. (VUB) Brussels. and University of Antwerp) ;
van der Flier, W.M. (Alzheimer Center Amsterdam. Department of Neurology. Amsterdam Neuroscience. Amsterdam UMC. Vrije Universiteit Amsterdam) ;
Landau, S. (Helen Wills Neuroscience Institute. University of California) ;
Popp, J. (Old Age Psychiatry. University Hospital of Lausanne) ;
Wallin, Anders (Institute of Neuroscience and Physiology. Sahlgrenska Academy at University of Gothenburg) ;
Scheltens, P. (Alzheimer Center Amsterdam. Department of Neurology. Amsterdam Neuroscience. Amsterdam UMC. Vrije Universiteit Amsterdam) ;
Rikkert, M.O. (Department of Geriatric Medicine. Radboud Alzheimer Center. Radboud University Medical Center) ;
Snyder, P.J. (Kingston. The University of Rhode Island) ;
Rowe, C. (Department of Molecular Imaging & Therapy. Austin Health) ;
Chételat, G.. (Institut National de la Santé et de la Recherche Médicale (Inserm)) ;
Ruíz, A. (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Marquié, M. (Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas) ;
Chipi, E. (Section of Neurology. Center for Memory Disturbances - Lab. of Clinical Neurochemistry. Department of Medicine and Surgery. University of Perugia) ;
Wolfsgruber, S. (Department of Neurodegenerative Diseases and Psychiatry. University Hospital Bonn) ;
Heneka, M. (Department of Neurodegenerative Diseases and Psychiatry. University Hospital Bonn) ;
Boecker, H. (Functional Neuroimaging Group. Department of Radiology. University Hospital Bonn) ;
Peters, O. (Charité - Universitätsmedizin Berlin) ;
Jarholm, J. (Department of Neurology. Akershus University Hospital) ;
Rami, L. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Tort-Merino, A. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Binette, A.P. (Centre for Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre) ;
Poirier, J. (Centre for Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre) ;
Rosa-Neto, P. (Centre for Studies on Prevention of Alzheimer's Disease (StOP-AD) Centre) ;
Cerman, J. (International Clinical Research Center. St. Anne's University Hospital) ;
Dubois, B. (AP-HP. Hôpital de la Pitié Salpêtrière. Institute of Memory and Alzheimer's Disease (IM2A). Centre of excellence of neurodegenerative disease (CoEN). Department of Neurology) ;
Teichmann, M. (AP-HP. Hôpital de la Pitié Salpêtrière. Institute of Memory and Alzheimer's Disease (IM2A). Centre of excellence of neurodegenerative disease (CoEN). Department of Neurology) ;
Alcolea, Daniel (Institut d'Investigació Biomèdica Sant Pau) ;
Fortea, Juan (Institut d'Investigació Biomèdica Sant Pau) ;
Sánchez-Saudinós, María Belén (Institut d'Investigació Biomèdica Sant Pau) ;
Ebenau, J. (Alzheimer Center Amsterdam. Department of Neurology. Amsterdam Neuroscience. Amsterdam UMC. Vrije Universiteit Amsterdam) ;
Pocnet, C. (Old Age Psychiatry. University Hospital of Lausanne) ;
Eckerström, M. (Institute of Neuroscience and Physiology. Sahlgrenska Academy at University of Gothenburg) ;
Thompson, L. (Kingston. The University of Rhode Island) ;
Villemagne, V. (Department of Psychiatry. University of Pittsburgh) ;
Buckley, R. (Brigham and Women's Hospital and Department of Neurology Massachusetts General Hospital. Harvard Medical School) ;
Burnham, S. (Section of Neurology. Center for Memory Disturbances - Lab. of Clinical Neurochemistry. Department of Medicine and Surgery. University of Perugia) ;
Delarue, M. (Institut National de la Sant. et de la Recherche M.dicale (Inserm)) ;
Freund-Levi, Yvonne (Department of Neurobiology. Care Sciences and Society. Karolinska Institutet) ;
Wallin, Å.K. (Department of Clinical Sciences Malmö. Clinical Memory Research Unit. Lund University) ;
Ramakers, I. (Maastricht University. School for Mental Health and Neuroscience) ;
Tsolaki, Magda (Memory and Dementia Center. 3rd Department of Neurology. "G Papanicolau. " General Hospital. Aristotle University of Thessaloniki) ;
Soininen, H. (Institute of Clinical Medicine. Neurology. University of Eastern Finland) ;
Hampel, H. (GRC no 21. Alzheimer Precision Medicine (AMP). AP-HP. Pitié-Salpêtrière Hospital. Sorbonne University) ;
Spiru, L. (Geriatrics- Gerontology and Old Age Psychiatry. Alzheimer Unit. Ana Aslan International Foundation - Memory Center and Longevity Medicine) ;
Tijms, B. (Maastricht University. School for Mental Health and Neuroscience) ;
Ossenkoppele, R. (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Verhey, F.R.J. (Maastricht University. School for Mental Health and Neuroscience) ;
Jessen, F. (German Center For Neurodegenerative Diseases/Clinical Research. Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE). Zentrum für klinische Forschung/AG) ;
Visser, P.J. (Department of Neurobiology. Care Sciences and Society. Karolinska Institutet)
Introduction: The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited. Methods: In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity. [...]
2022 -  10.1002/alz.12512
Alzheimer's & Dementia, Vol. 18 Núm. 10 (october 2022) , p. 1832-1845
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
